Michael Albert, MD
Family Medicine · Richland, MSNPI 1679562094
Payments from drug & device makers
Across 171 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$412
- Otsuka America Pharmaceutical, Inc.$306
- Sunovion Pharmaceuticals Inc.$239
- Teva Pharmaceuticals USA, Inc.$223
- UCB, Inc.$190
- Bayer$169
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $412 |
| Otsuka America Pharmaceutical, Inc. | 15 | $306 |
| Sunovion Pharmaceuticals Inc. | 24 | $239 |
| Teva Pharmaceuticals USA, Inc. | 11 | $223 |
| UCB, Inc. | 4 | $190 |
| Bayer | 10 | $169 |
| Lilly USA, LLC | 9 | $140 |
| Astellas Pharma US Inc | 7 | $129 |
| Novo Nordisk | 7 | $119 |
| Neurocrine Biosciences, Inc. | 4 | $109 |
| Avanir Pharmaceuticals, Inc. | 5 | $103 |
| Smith+Nephew | 4 | $100 |
| Lundbeck LLC | 3 | $98 |
| Novartis | 4 | $82 |
| Sumitomo Pharma America, Inc. | 6 | $79 |
| Pfizer | 5 | $77 |
| Eisai Inc. | 4 | $68 |
| Exact Sciences | 3 | $54 |
| GSK | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Boehringer Ingelheim | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Philips North America LLC | 2 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nayzilam$124
How this compares
$3,014 in reported general payments places this provider in the 75th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,243 | $474,660 |
| NuedextaDextromethorphan Hbr/Quinidine | 255 | $120,909 |
| EntrestoSacubitril/Valsartan | 381 | $97,227 |
| XareltoRivaroxaban | 320 | $92,226 |
| JardianceEmpagliflozin | 276 | $70,918 |
| OzempicSemaglutide | 70 | $69,472 |
| JanuviaSitagliptin Phosphate | 312 | $69,401 |
| FarxigaDapagliflozin Propanediol | 280 | $66,916 |
| BenlystaBelimumab | 34 | $65,960 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $61,559 |
| MyrbetriqMirabegron | 295 | $59,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $58,459 |
| LinzessLinaclotide | 81 | $46,244 |
| TradjentaLinagliptin | 157 | $39,719 |
| Atorvastatin Calcium | 4,929 | $36,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $77 | $490,0972,297 claims |
| GSKBenlysta, Trelegy Ellipta, Breo Ellipta | $50 | $148,712177 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $30 | $128,911446 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $103 | $120,909255 claims |
| NovartisEntresto | $82 | $97,227381 claims |
| AbbVieLinzess, Restasis | $412 | $73,919136 claims |
| Novo NordiskOzempic | $119 | $69,47270 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $59,200295 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $140 | $46,9951,324 claims |
| Smith+NephewSantyl | $100 | $18,63826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Richland
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.